299 related articles for article (PubMed ID: 25013998)
1. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.
Fleseriu M; Findling JW; Koch CA; Schlaffer SM; Buchfelder M; Gross C
J Clin Endocrinol Metab; 2014 Oct; 99(10):3718-27. PubMed ID: 25013998
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
3. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
4. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
[TBL] [Abstract][Full Text] [Related]
5. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
Clin Endocrinol (Oxf); 2010 Jan; 72(1):70-5. PubMed ID: 19453623
[TBL] [Abstract][Full Text] [Related]
6. The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging.
Testa RM; Albiger N; Occhi G; Sanguin F; Scanarini M; Berlucchi S; Gardiman MP; Carollo C; Mantero F; Scaroni C
Eur J Endocrinol; 2007 Feb; 156(2):241-8. PubMed ID: 17287414
[TBL] [Abstract][Full Text] [Related]
7. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
8. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
Woo YS; Isidori AM; Wat WZ; Kaltsas GA; Afshar F; Sabin I; Jenkins PJ; Monson JP; Besser GM; Grossman AB
J Clin Endocrinol Metab; 2005 Aug; 90(8):4963-9. PubMed ID: 15886242
[TBL] [Abstract][Full Text] [Related]
10. The Treatment of Cushing's Disease.
Pivonello R; De Leo M; Cozzolino A; Colao A
Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
[TBL] [Abstract][Full Text] [Related]
11. Crooke's Changes In Cushing's Syndrome Depends on Degree of Hypercortisolism and Individual Susceptibility.
Oldfield EH; Vance ML; Louis RG; Pledger CL; Jane JA; Lopes MB
J Clin Endocrinol Metab; 2015 Aug; 100(8):3165-71. PubMed ID: 26147609
[TBL] [Abstract][Full Text] [Related]
12. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
[TBL] [Abstract][Full Text] [Related]
13. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay.
Kojima Y; Suzuki S; Yamamura K; Ohhashi G; Yamamoto I
Endocr J; 2002 Jun; 49(3):285-92. PubMed ID: 12201210
[TBL] [Abstract][Full Text] [Related]
16. Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing's disease harbouring microadenomas or macroadenomas.
Machado MC; Alcantara AE; Pereira AC; Cescato VA; Castro Musolino NR; de Mendonça BB; Bronstein MD; Fragoso MC
J Endocrinol Invest; 2016 Dec; 39(12):1401-1409. PubMed ID: 27363699
[TBL] [Abstract][Full Text] [Related]
17. Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease.
Ferrau F; Trimarchi F; Cannavo S
Endocrine; 2014 Nov; 47(2):550-6. PubMed ID: 24408052
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
[TBL] [Abstract][Full Text] [Related]
20. FSH-producing macroadenoma associated in a patient with Cushing's disease.
Oyama K; Yamada S; Hukuhara N; Hiramatsu R; Taguchi M; Yazawa M; Matsuda A; Ohmura E; Imai Y
Neuro Endocrinol Lett; 2006 Dec; 27(6):733-6. PubMed ID: 17187002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
